Global Fingolimod Hydrochloride Capsules 麻豆原创 Research Report 2024

Publication ID:

PB509240414

Publication Date:

September 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Fingolimod hydrochloride capsules are a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older
The global Fingolimod Hydrochloride Capsules market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Fingolimod Hydrochloride Capsules is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Fingolimod Hydrochloride Capsules is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Fingolimod Hydrochloride Capsules include Novartis, HEC Pharm, Biocon, Sun Pharmaceutical, Mylan, Zentiva, Teva, Apotex, Puren Pharma, Sun Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fingolimod Hydrochloride Capsules, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fingolimod Hydrochloride Capsules.
The Fingolimod Hydrochloride Capsules market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Fingolimod Hydrochloride Capsules market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fingolimod Hydrochloride Capsules manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novartis
HEC Pharm
Biocon
Sun Pharmaceutical
Mylan
Zentiva
Teva
Apotex
Puren Pharma
Sun Pharmaceuticals
Dr. Reddy's Laboratories
Aurobindo Pharma
Viatris Healthcare
Segment by Type
0.25mg per Unit
0.5mg per Unit
Segment by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Fingolimod Hydrochloride Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Fingolimod Hydrochloride Capsules in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Fingolimod Hydrochloride Capsules 麻豆原创 Overview
1.1 Product Definition
1.2 Fingolimod Hydrochloride Capsules by Type
1.2.1 Global Fingolimod Hydrochloride Capsules 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 0.25mg per Unit
1.2.3 0.5mg per Unit
1.3 Fingolimod Hydrochloride Capsules by Application
1.3.1 Global Fingolimod Hydrochloride Capsules 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Fingolimod Hydrochloride Capsules 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Fingolimod Hydrochloride Capsules Revenue 2019-2030
1.4.2 Global Fingolimod Hydrochloride Capsules Sales 2019-2030
1.4.3 Global Fingolimod Hydrochloride Capsules 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Fingolimod Hydrochloride Capsules 麻豆原创 Competition by Manufacturers
2.1 Global Fingolimod Hydrochloride Capsules Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Fingolimod Hydrochloride Capsules Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Fingolimod Hydrochloride Capsules Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Fingolimod Hydrochloride Capsules, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Fingolimod Hydrochloride Capsules, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Fingolimod Hydrochloride Capsules, Product Type & Application
2.7 Global Key Manufacturers of Fingolimod Hydrochloride Capsules, Date of Enter into This Industry
2.8 Global Fingolimod Hydrochloride Capsules 麻豆原创 Competitive Situation and Trends
2.8.1 Global Fingolimod Hydrochloride Capsules 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Fingolimod Hydrochloride Capsules Players 麻豆原创 Share by Revenue
2.8.3 Global Fingolimod Hydrochloride Capsules 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Fingolimod Hydrochloride Capsules 麻豆原创 Scenario by Region
3.1 Global Fingolimod Hydrochloride Capsules 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Fingolimod Hydrochloride Capsules Sales by Region: 2019-2030
3.2.1 Global Fingolimod Hydrochloride Capsules Sales by Region: 2019-2024
3.2.2 Global Fingolimod Hydrochloride Capsules Sales by Region: 2025-2030
3.3 Global Fingolimod Hydrochloride Capsules Revenue by Region: 2019-2030
3.3.1 Global Fingolimod Hydrochloride Capsules Revenue by Region: 2019-2024
3.3.2 Global Fingolimod Hydrochloride Capsules Revenue by Region: 2025-2030
3.4 North America Fingolimod Hydrochloride Capsules 麻豆原创 Facts & Figures by Country
3.4.1 North America Fingolimod Hydrochloride Capsules 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Fingolimod Hydrochloride Capsules Sales by Country (2019-2030)
3.4.3 North America Fingolimod Hydrochloride Capsules Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Fingolimod Hydrochloride Capsules 麻豆原创 Facts & Figures by Country
3.5.1 Europe Fingolimod Hydrochloride Capsules 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Fingolimod Hydrochloride Capsules Sales by Country (2019-2030)
3.5.3 Europe Fingolimod Hydrochloride Capsules Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Fingolimod Hydrochloride Capsules 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Fingolimod Hydrochloride Capsules 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Fingolimod Hydrochloride Capsules Sales by Region (2019-2030)
3.6.3 Asia Pacific Fingolimod Hydrochloride Capsules Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Fingolimod Hydrochloride Capsules 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Fingolimod Hydrochloride Capsules 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Fingolimod Hydrochloride Capsules Sales by Country (2019-2030)
3.7.3 Latin America Fingolimod Hydrochloride Capsules Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Fingolimod Hydrochloride Capsules 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Fingolimod Hydrochloride Capsules 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Fingolimod Hydrochloride Capsules Sales by Country (2019-2030)
3.8.3 Middle East and Africa Fingolimod Hydrochloride Capsules Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Fingolimod Hydrochloride Capsules Sales by Type (2019-2030)
4.1.1 Global Fingolimod Hydrochloride Capsules Sales by Type (2019-2024)
4.1.2 Global Fingolimod Hydrochloride Capsules Sales by Type (2025-2030)
4.1.3 Global Fingolimod Hydrochloride Capsules Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Fingolimod Hydrochloride Capsules Revenue by Type (2019-2030)
4.2.1 Global Fingolimod Hydrochloride Capsules Revenue by Type (2019-2024)
4.2.2 Global Fingolimod Hydrochloride Capsules Revenue by Type (2025-2030)
4.2.3 Global Fingolimod Hydrochloride Capsules Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Fingolimod Hydrochloride Capsules Price by Type (2019-2030)
5 Segment by Application
5.1 Global Fingolimod Hydrochloride Capsules Sales by Application (2019-2030)
5.1.1 Global Fingolimod Hydrochloride Capsules Sales by Application (2019-2024)
5.1.2 Global Fingolimod Hydrochloride Capsules Sales by Application (2025-2030)
5.1.3 Global Fingolimod Hydrochloride Capsules Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Fingolimod Hydrochloride Capsules Revenue by Application (2019-2030)
5.2.1 Global Fingolimod Hydrochloride Capsules Revenue by Application (2019-2024)
5.2.2 Global Fingolimod Hydrochloride Capsules Revenue by Application (2025-2030)
5.2.3 Global Fingolimod Hydrochloride Capsules Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Fingolimod Hydrochloride Capsules Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Fingolimod Hydrochloride Capsules Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 HEC Pharm
6.2.1 HEC Pharm Company Information
6.2.2 HEC Pharm Description and Business Overview
6.2.3 HEC Pharm Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.2.4 HEC Pharm Fingolimod Hydrochloride Capsules Product Portfolio
6.2.5 HEC Pharm Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Company Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocon Fingolimod Hydrochloride Capsules Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Sun Pharmaceutical
6.4.1 Sun Pharmaceutical Company Information
6.4.2 Sun Pharmaceutical Description and Business Overview
6.4.3 Sun Pharmaceutical Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sun Pharmaceutical Fingolimod Hydrochloride Capsules Product Portfolio
6.4.5 Sun Pharmaceutical Recent Developments/Updates
6.5 Mylan
6.5.1 Mylan Company Information
6.5.2 Mylan Description and Business Overview
6.5.3 Mylan Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mylan Fingolimod Hydrochloride Capsules Product Portfolio
6.5.5 Mylan Recent Developments/Updates
6.6 Zentiva
6.6.1 Zentiva Company Information
6.6.2 Zentiva Description and Business Overview
6.6.3 Zentiva Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Zentiva Fingolimod Hydrochloride Capsules Product Portfolio
6.6.5 Zentiva Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Teva Fingolimod Hydrochloride Capsules Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Apotex
6.8.1 Apotex Company Information
6.8.2 Apotex Description and Business Overview
6.8.3 Apotex Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Apotex Fingolimod Hydrochloride Capsules Product Portfolio
6.8.5 Apotex Recent Developments/Updates
6.9 Puren Pharma
6.9.1 Puren Pharma Company Information
6.9.2 Puren Pharma Description and Business Overview
6.9.3 Puren Pharma Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Puren Pharma Fingolimod Hydrochloride Capsules Product Portfolio
6.9.5 Puren Pharma Recent Developments/Updates
6.10 Sun Pharmaceuticals
6.10.1 Sun Pharmaceuticals Company Information
6.10.2 Sun Pharmaceuticals Description and Business Overview
6.10.3 Sun Pharmaceuticals Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sun Pharmaceuticals Fingolimod Hydrochloride Capsules Product Portfolio
6.10.5 Sun Pharmaceuticals Recent Developments/Updates
6.11 Dr. Reddy's Laboratories
6.11.1 Dr. Reddy's Laboratories Company Information
6.11.2 Dr. Reddy's Laboratories Description and Business Overview
6.11.3 Dr. Reddy's Laboratories Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dr. Reddy's Laboratories Fingolimod Hydrochloride Capsules Product Portfolio
6.11.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.12 Aurobindo Pharma
6.12.1 Aurobindo Pharma Company Information
6.12.2 Aurobindo Pharma Description and Business Overview
6.12.3 Aurobindo Pharma Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Aurobindo Pharma Fingolimod Hydrochloride Capsules Product Portfolio
6.12.5 Aurobindo Pharma Recent Developments/Updates
6.13 Viatris Healthcare
6.13.1 Viatris Healthcare Company Information
6.13.2 Viatris Healthcare Description and Business Overview
6.13.3 Viatris Healthcare Fingolimod Hydrochloride Capsules Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Viatris Healthcare Fingolimod Hydrochloride Capsules Product Portfolio
6.13.5 Viatris Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Fingolimod Hydrochloride Capsules Industry Chain Analysis
7.2 Fingolimod Hydrochloride Capsules Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Fingolimod Hydrochloride Capsules Production Mode & Process
7.4 Fingolimod Hydrochloride Capsules Sales and 麻豆原创ing
7.4.1 Fingolimod Hydrochloride Capsules Sales Channels
7.4.2 Fingolimod Hydrochloride Capsules Distributors
7.5 Fingolimod Hydrochloride Capsules Customers
8 Fingolimod Hydrochloride Capsules 麻豆原创 Dynamics
8.1 Fingolimod Hydrochloride Capsules Industry Trends
8.2 Fingolimod Hydrochloride Capsules 麻豆原创 Drivers
8.3 Fingolimod Hydrochloride Capsules 麻豆原创 Challenges
8.4 Fingolimod Hydrochloride Capsules 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Novartis
HEC Pharm
Biocon
Sun Pharmaceutical
Mylan
Zentiva
Teva
Apotex
Puren Pharma
Sun Pharmaceuticals
Dr. Reddy's Laboratories
Aurobindo Pharma
Viatris Healthcare

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.